APX2014 (APX-2014) is a novel potent inhibitor of reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) with IC50 of 0.2 uM for redox EMSA inhibition.

APX2009 (APX-2009) is a novel potent inhibitor of reduction-oxidation factor 1-apurinic/apyrimidinic endonuclease 1 (Ref-1/APE1) with IC50 of 0.45 uM for redox EMSA inhibition.

APTO-253 is a small molecule inducer of KLF4, stabilizes G-quadruplex DNA and reduces MYC mRNA expression and protein levels.

APTO-253 is a novel small molecule with potent anti-tumor activity in cancer cells via induction of the gene that expresses the Krüppel-like factor 4 (KLF4) master transcription factor, leading to cell cycle inhibition and programmed cell death.

Aprotinin is a serine protease inhibitor isolated from bovine lung which inhibits trypsin and chymotrypsin with Ki values of 0.06 pM and 9 nM, respectively.

Apricitabine is a novel nucleoside reverse transcriptase inhibitor for the treatment of HIV infection that is refractory to existing drugs

Apogossypol (NSC 736630) is a Bcl-2 family antagonist that binds to Bcl-XL, Bcl-2 and Bcl-xL with IC50 of 2.6, 2.8 and 3.69 uM, respectively.

Aplaviroc (GSK-873140.

apelin receptor.

APD916 is a potent and selective antagonist of the H3 receptor with Ki of 0.7 nM for rH3R.

APD-371 (APD371, Olorinab) is a potent, selective and orally available CB2 agonist with EC50 of 6.2 nM; displays no activity against CB1 receptors (EC50>10 uM); exhibits activity in rat model of osteoarthritis pain.

APA modulator T5 is a small modulator of alternative polyadenylation (APA), modulates endogenous APA via nonkinase-mediated pathways and promotes distal-to-proximal (DtoP) APA usage in multiple transcripts.

APA modulator T4 is a small modulator of alternative polyadenylation (APA) with IC50 of 2.1 uM in reporter assays, modulates endogenous APA via nonkinase-mediated pathways and promotes distal-to-proximal (DtoP) APA usage in multiple transcripts.

AP219 is a control compound for AP39, containing the triphenylphosphonium scaffold but lacking the H2S-releasing portion.

AP14145 (AP-14145) is a potent, selective negative allosteric modulator of KCa2.2 and KCa2.3 with equal potency (IC50=1.1±0.3 uM).

AOH1160 is a potent, first-in-class, orally available small molecule inhibitor of Proliferating cell nuclear antigen (PCNA).

ANY1 (FosA inhibitor ANY1) is a small molecule active site inhibitor of FosA (metal-dependent glutathione S-transferase) with IC50 of 5.1 uM (K. pneumoniae FosA).

Antimycin A is an inhibitor of cellular respiration, specifically oxidative phosphorylation, binds to the Qi site of cytochrome c reductase, disrupts the Q-cycle of enzyme turn over.

Antimalarial compound 49c is a potent antimalarial peptidomimetic inhibitor originally developed against Plasmepsin II selectively targets TgASP3, PfPMIX, and PfPMX, shows very potent antimalarial effects only after 72 h of treatment with IC50 of 0.6 nM.

antifungal.

ANT431 sodium is a novel, highly water-soluble metallo-β-lactamase (MBL) inhibitor with IC50 of 290 nM and 195 nM for NDM-1 and VIM-2, shows a comparatively weak inhibitor of VIM-1 and IMP-1 (Ki of 14.6 and 4.15 uM, respectively).

Anguizole is a HCV NS4B inhibitor targeting second amphipathic helix of NS4B (NS4B-AH2), blocks genotype 1b HCV replication with EC50 of 310 nM.

Angiotensin II human is a peptide hormone that causes vasoconstriction and a subsequent increase in blood pressure.

Angiotensin (1-7) (Ang-(1-7)) is an active heptapeptide of the Renin-angiotensin system (RAS), inhibits purified canine angiotensin converting enzyme (ACE) activity with IC50 of 0.65 uM.

Anemarsaponin E is extracted from Anemarrhena asphodeloides Bunge and has anti-inflammatory activity.

Anemarrhenasaponin I, a traditional Chinese medicine, is isolated from Anemarrhena asphodeloides Bunge.

Anagrelide Hydrochloride(BL4162A) is a drug used for the treatment of essential thrombocytosis.

Anagliptin is a potent and selective DPP-4 inhibitor(IC50= 3.8 nM); > 10 fold less potent for DPP-8 and DPP-9.

AN2718 inhibits fungal growth by blocking protein synthesis using the oxaborole tRNA trapping (OBORT) mechanism.

AN-2690(Tavaborole), an antifungal agent with activity against Trichophyton species, in a topical solution formulation, for the potential treatment of onychomycosis.